ERT1 Antibody

What is Endothelin-1 and why are antibodies against it important in research?

Endothelin-1 (ET-1) is a powerful vasoconstrictor peptide that belongs to the endothelin system, which comprises three active peptides (ET-1, ET-2, and ET-3). These peptides mediate their actions via two specific G-protein coupled receptors: ET₍A₎R and ET₍B₎R. Both receptors are present at similar levels in human myocardium and heart tissues .

ET-1 antibodies are crucial research tools because they enable investigation of endothelin's diverse biological activities beyond vasoconstriction, including:

• Modulation of mitogenesis

• Regulation of apoptotic pathways

• Promotion of angiogenesis

• Influence on tumor invasion and metastasis development

In cardiovascular research, ET-1 has particular significance as elevated plasma ET-1 levels have been associated with increased mortality in acute heart failure patients . Additionally, ET-1 expression has been detected in complex regional pain syndrome patients, suggesting its role in pain modulation and inflammation .

What types of Endothelin antibodies are available for research applications?

Several types of Endothelin antibodies are available, each optimized for specific experimental applications:

The choice between these antibody types depends on the experimental question and technique. For instance, when developing sandwich ELISA assays, specific antibody pairs (like MAB3440 as capture and MAB34401 as detection) are recommended for optimal sensitivity and specificity .

How do ET-1 receptor antibodies differ in their target specificity?

Endothelin receptor antibodies differ significantly in their specificity for recognizing the two main receptor subtypes:

ET₍A₎R antibodies typically target the intracellular C-terminus region. For example, the AER-001 antibody targets the peptide sequence (C)NHNTERSSHKDSMN, corresponding to amino acid residues 413-426 of rat ET₍A₎R . This specificity is important because ET₍A₎R has varying affinities for endothelin isoforms (ET-1>ET-2>ET-3) .

In contrast, ET₍B₎R antibodies target distinct epitopes specific to this receptor subtype. Unlike ET₍A₎R, the ET₍B₎R shows no selective affinity among the endothelin isoforms .

When selecting an antibody, it's critical to match the specificity with the biological question being investigated. For studies focusing on differential signaling between receptor subtypes, highly specific antibodies that do not cross-react are essential.

What are the recommended storage conditions for maintaining ET-1 antibody efficacy?

Proper storage is crucial for maintaining antibody performance over time. Based on manufacturer recommendations:

• Use a manual defrost freezer and avoid repeated freeze-thaw cycles

• Store unopened antibodies at -20°C to -70°C for up to 12 months from receipt date

• After reconstitution, store at 2-8°C under sterile conditions for up to 1 month

• For long-term storage after reconstitution, aliquot and maintain at -20°C to -70°C for up to 6 months

Improper storage can significantly impact antibody performance. For example, extended storage of the 14C8 antibody clone resulted in loss of its ability to recognize recombinant ERβ protein, demonstrating how storage conditions directly affect antibody functionality .

How can I validate the specificity of an ET-1 antibody for my experiments?

A rigorous validation approach employing multiple methods is essential for confirming antibody specificity. Based on best practices in antibody validation, the following workflow is recommended:

• Control cell lines/tissues testing:

  • Use positive controls with confirmed ET-1 expression by RNA-seq or qPCR

  • Include negative controls lacking ET-1 expression

  • Test both in the experimental application (IHC, WB, ELISA)

• Western blot validation:

  • Include recombinant ET-1 protein as reference

  • Verify single band of expected size (~60 kDa for ET-1)

  • Check for absence of bands in negative controls

  • Be suspicious of multiple bands, which often indicate non-specific binding

• Immunoprecipitation followed by mass spectroscopy (IP-MS):

  • This gold-standard approach identifies the actual proteins bound by the antibody

  • Confirms on-target binding and reveals off-target interactions

• Cross-application testing:

  • Test antibody performance across multiple applications (IHC, WB, ELISA)

  • An antibody that performs well in one application may not be specific in another

To illustrate, in a comprehensive validation study of ERβ antibodies (which serves as a model for rigorous validation), only 1 of 13 tested antibodies showed sufficient specificity when subjected to this multi-method validation approach .

What methodological approaches should be used when developing sandwich ELISA assays with ET-1 antibodies?

Developing effective sandwich ELISA assays for ET-1 detection requires careful consideration of antibody pairs and optimization steps:

• Antibody pair selection:

  • Use antibodies targeting different epitopes of ET-1

  • For optimal results, pair MAB3440 (clone 3G10) as the capture antibody with MAB34401 as the detection antibody

• Standard curve development:

  • Use serially diluted recombinant Human Endothelin-1 protein (2-fold dilutions)

  • Capture with anti-ET-1 C-terminus antibody (e.g., MAB3440)

  • Detect with biotinylated anti-ET-1 antibody (e.g., MAB34401)

  • Visualize with Streptavidin-HRP followed by substrate solution

• Assay optimization:

  • Titrate antibody concentrations to determine optimal coating concentration

  • Test different blocking buffers to minimize background

  • Optimize sample dilutions for your specific sample type

  • Include blank, negative, and positive controls

• Validation:

  • Determine assay sensitivity, dynamic range, and lower limit of detection

  • Test for interference from sample matrix components

  • Verify results with orthogonal methods when possible

For researchers requiring standardized approaches, commercial ELISA development kits like the Endothelin Pan Specific DuoSet (DY1160) or the Endothelin-1 Quantikine ELISA Kit (DET100) provide optimized components and protocols .

How do I interpret discrepancies between ET-1 mRNA expression and protein detection?

Discrepancies between mRNA and protein expression levels for ET-1 are common and can arise from multiple factors:

• Post-transcriptional regulation:

  • mRNA may be transcribed but not efficiently translated

  • microRNAs can suppress translation without affecting mRNA levels

  • Alternative splicing can generate protein variants not detected by some antibodies

• Antibody specificity issues:

  • False-positive protein detection due to cross-reactivity with similar proteins

  • False-negatives due to epitope masking or protein modifications

  • Antibody binding to different isoforms than those detected by mRNA assays

• Methodological considerations:

  • Different sensitivity thresholds between mRNA detection methods and protein assays

  • Sample preparation differences affecting protein detection

  • Different detection limits between techniques

To resolve such discrepancies:

• Validate your antibody using multiple approaches (as detailed in question 2.1)

• Use multiple antibodies targeting different epitopes of the same protein

• Employ orthogonal protein detection methods (e.g., MS-based proteomics)

• Consider using genetic knockout/knockdown models as definitive controls

A study on ERβ found that despite detectable mRNA, many antibodies showed discordant protein expression patterns, highlighting the critical importance of rigorous antibody validation .

What are the critical factors for accurate immunohistochemical detection of ET-1 in tissue samples?

Successful immunohistochemical detection of ET-1 in tissues requires attention to several critical factors:

• Antibody selection:

  • Choose antibodies specifically validated for IHC applications

  • Monoclonal antibodies often provide better specificity compared to polyclonals

  • Clone 3G10 (MAB3440) has been successfully used for ET-1 detection in tissues

• Tissue preparation and fixation:

  • Consistent fixation protocols (typically 10% neutral buffered formalin)

  • Optimal fixation duration (neither under nor over-fixed)

  • Appropriate antigen retrieval methods (heat-induced or enzymatic)

• Controls:

  • Positive control tissues with known ET-1 expression (e.g., HUVEC cells, lung tissue)

  • Negative control tissues lacking ET-1 expression

  • Technical negative controls (primary antibody omitted)

  • Blocking peptide controls to demonstrate specificity

• Detection system optimization:

  • Signal amplification systems for low-abundance targets

  • Appropriate counterstaining to visualize tissue architecture

  • Optimal antibody concentration determined by titration

• Result interpretation:

  • Understand expected localization patterns (e.g., ET-1 is expressed in respiratory epithelium and smooth muscle in rat lung)

  • Consider dual staining with cell-type markers (e.g., CD31 for endothelial cells)

  • Quantify expression using appropriate image analysis tools

For example, in CRPS patient skin samples, double staining for CD31 (red, marking blood vessels) and ET-1 (blue) enabled precise localization of ET-1-positive cells in relation to vasculature .

How are advanced antibody design approaches improving ET-1 detection specificity?

Recent advances in antibody design are enhancing the specificity and performance of antibodies, including those for ET-1 detection:

• De novo design approaches:

  • OptCDR (Optimal Complementarity Determining Regions) computational method designs CDRs to recognize specific epitopes

  • Backbone conformations are predicted to interact favorably with target antigens

  • Amino acid selection for CDR positions uses rotamer libraries

  • This approach generates multiple CDR sequence sets that can be grafted onto antibody scaffolds

• Hybrid design-and-screening approaches:

  • Strategic randomization of CDR positions to create focused libraries

  • Introduction of constrained sequences (like RGD motifs) within CDRs

  • Use of disulfide bonds to constrain loop conformations

  • Screening of these rational libraries using display technologies

• Key mutations for enhanced performance:

  • Elimination of unsatisfied polar residues in CDRs

  • Introduction or removal of charged residues peripheral to antigen contacts

  • Optimization of residues outside the binding interface to improve on-rates

• Stability engineering:

  • Combined approaches including knowledge-based, statistical, and structure-based methods

  • Targeted mutations can significantly increase melting temperature (e.g., P101D in VH increased Tm from 51°C to 67°C)

  • Combinations of mutations can be synergistic (e.g., S16E, V55G, P101D in VH, and S46L in VL increased Tm to 82°C)

These advanced design approaches, while not yet routinely applied to ET-1 antibodies specifically, represent important advances that are likely to improve future generations of antibodies for ET-1 and its receptors.